Description

UDILIV 300 MG (1×15)

Indications

UDILIV 300 MG is primarily indicated for the treatment of various liver disorders, including cholestasis, a condition characterized by impaired bile flow. It is also used in the management of primary biliary cholangitis and to support liver function in patients with hepatic impairment. Additionally, UDILIV may be prescribed for the treatment of gallstones, particularly in patients who are not candidates for surgical intervention.

Mechanism of Action

The active ingredient in UDILIV, Ursodeoxycholic acid (UDCA), is a naturally occurring bile acid. Its mechanism of action involves several pathways that contribute to its therapeutic effects. UDCA reduces the concentration of toxic bile acids in the liver and promotes bile flow, thereby alleviating cholestasis. It also has a cytoprotective effect on hepatocytes, enhancing liver cell survival and function. Furthermore, UDCA aids in the dissolution of cholesterol gallstones by reducing cholesterol saturation in bile and increasing bile acid solubility.

Pharmacological Properties

UDILIV 300 MG exhibits several pharmacological properties that make it effective in managing liver disorders. It is well absorbed in the gastrointestinal tract, with peak plasma concentrations occurring approximately 1-3 hours post-administration. The drug undergoes enterohepatic circulation, which enhances its therapeutic effects. UDCA is metabolized in the liver and excreted primarily in the bile. Its half-life ranges from 3 to 5 hours, allowing for once or twice daily dosing in most patients.

Contraindications

UDILIV 300 MG is contraindicated in patients with known hypersensitivity to Ursodeoxycholic acid or any of the excipients in the formulation. It should not be used in individuals with severe liver dysfunction, acute inflammation of the gallbladder, or biliary obstruction. Additionally, it is not recommended for use in patients with active peptic ulcer disease or those with a history of gallbladder disease that may lead to complications.

Side Effects

While UDILIV 300 MG is generally well tolerated, some patients may experience side effects. Common side effects include gastrointestinal disturbances such as diarrhea, nausea, and abdominal discomfort. In rare cases, patients may experience allergic reactions, including rash, pruritus, or urticaria. Liver enzyme elevations have been reported, necessitating regular monitoring of liver function during treatment. If any severe or persistent side effects occur, patients should consult their healthcare provider immediately.

Dosage and Administration

The recommended dosage of UDILIV 300 MG varies depending on the specific condition being treated. For cholestatic liver diseases, the typical starting dose is 300 mg taken orally once daily, which may be adjusted based on clinical response and tolerance. In cases of gallstones, the usual dose is 8-10 mg/kg body weight per day, divided into two or three doses. It is important to take UDILIV with food to enhance absorption. Patients should adhere to the prescribed regimen and consult their healthcare provider for any necessary adjustments.

Interactions

UDILIV 300 MG may interact with certain medications, potentially altering their effectiveness or increasing the risk of side effects. Notable interactions include cholestyramine, which can reduce the absorption of UDCA, and antacids containing aluminum, which may also interfere with its efficacy. Additionally, drugs that affect liver enzymes, such as cyclosporine and certain anticonvulsants, may alter UDCA metabolism. Therefore, patients should inform their healthcare provider of all medications they are taking, including over-the-counter drugs and supplements, to avoid potential interactions.

Precautions

Before starting UDILIV 300 MG, patients should be evaluated for any pre-existing liver conditions. Regular monitoring of liver function tests is recommended, especially in patients with a history of liver disease. Caution should be exercised in patients with a history of gallbladder disease, as UDCA may lead to the dissolution of gallstones, which can cause complications if the stones become lodged in the bile ducts. Pregnant and breastfeeding women should use UDILIV only if the potential benefits outweigh the risks, and it should be used under the supervision of a healthcare provider.

Clinical Studies

Numerous clinical studies have evaluated the efficacy and safety of UDILIV 300 MG in various liver disorders. A randomized controlled trial demonstrated that UDCA significantly improved liver function tests in patients with primary biliary cholangitis compared to placebo. Another study showed that UDCA was effective in dissolving cholesterol gallstones in a significant percentage of patients when used over a prolonged period. Long-term follow-up studies have indicated that UDCA can reduce the progression of liver disease and improve overall liver health in patients with cholestatic liver disorders.

Conclusion

UDILIV 300 MG is a valuable therapeutic option for patients suffering from liver disorders, particularly those involving cholestasis and gallstones. Its mechanism of action, pharmacological properties, and clinical efficacy make it an essential component of liver disease management. However, as with any medication, it is crucial for patients to use UDILIV responsibly, under the guidance of a healthcare professional, to minimize potential risks and maximize therapeutic benefits.